Where Is The Corporate Integrity Agreement?

Law360, New York (February 27, 2012, 1:35 PM ET) -- In the most recent of a long line of False Claims Act whistleblower settlements involving allegations of shenanigans with government price reporting metrics, on Feb. 8, the U.S. Department of Justice announced that Dava Pharmaceuticals Inc. agreed to pay the United States $11 million to settle claims that it misreported prices in order to reduce its Medicaid Drug Rebate liability.

Specifically, the settlement alleges that Dava treated three of its branded drugs — cefdinir, clarithromycin and methotrexate — as generics, thereby lowering the percentage rebate owed...
To view the full article, register now.